STING1 and neoplasm: Delivery of CAR-T cells along with the STING agonist enhances endogenous immune responses against non-CAR-targeted antigens, driving BATF3 DC1-dependent tumor control, creating a pro-inflammatory microenvironment and epitope spreading [125,126,127].